Media, News
Major milestones Prescient Therapeutics (ASX:PTX) eyes in 2023
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is guided by its mission to develop novel, personalised therapies for multiple types of cancers. The company’s platform consists of targeted…
Article, News
Inside Prescient Therapeutics’ (ASX:PTX) clinical progress to cancer treatment
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) is focused on developing its innovative pipeline in personalised medicine to address significant unmet needs. The company’s development portfolio comprises cell…
Article, News
Year in Review: Prescient Therapeutics (ASX:PTX) with CEO and managing director, Steven Yatomi-Clarke
Stockhead’s Year in Review video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. …
Article, News
Prescient Therapeutics provides PTX-100 trial update, readies for investor briefing
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a partial response, meaning the size of the cancer tumour has…
Article, News
Prescient (ASX:PTX) closes a very productive September quarter, achieving key milestones
Prescient Therapeutics (ASX:PTX), an Australian biotech player developing personalised medicine therapies for cancer, has published its report for the September quarter. The company sees the…
Article, News
ASX Quarterlies: Nuheara rockets 33pc, Dicker continues to grow, while these biotechs are all cashed up
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings lodgements. To save you the trouble of trudging through it…
Article, News
Prescient’s (ASX:PTX) PTX-100 demonstrates encouraging clinical activity in T cell lymphomas
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical activity of PTX-100, one of the targeted therapies of Prescient. PTX-100…
Article, News
Prescient Therapeutics PTX-100 continues to exhibit excellent safety profile
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed…
Article, News
Prescient shows that PTX-100 is safe and effective on difficult to treat T-cell lymphomas
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed…
Article, News
Prescient Therapeutics’ PTX-100 expansion cohort continues to deliver on safety and clinical movement
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion cohort targeting relapsed and refractory T cell lymphoma (TCL) – and…